Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term follow-up study of sotatercept added to background therapy for pulmonary arterial hypertension
MOH_2021-05-05_009921Phase 3Not yet recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Acceleron Pharma Inc. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2021-05-05_009921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-05_009921.